The summit, co-hosted by BioCentury and BayHelix (Hundred Talents Association), saw the award being selected by the drug development industry to recognize Structure Therapeutics’ advancement in the research and development of small molecule drugs targeting G protein-coupled receptors (GPCRs) through its structure-based drug design platform. This award is a testament to the outstanding research and development capabilities of Structure Therapeutics.
On this joyful occasion, Concora is greatly inspired and looks forward to continuing to work hand in hand with Structure Therapeutics, expanding the path of innovation together, and contributing more to the development of the life sciences field.
Dr. Raymond Stevens, Founder and CEO of Structure Therapeutics, stated,
“This prestigious award is a testament to our R&D team’s exceptional performance, our strong innovative culture, and the talent of our employees. These efforts have propelled the development of GS-BR-1290, making it a promising, differentiated oral GLP-1 receptor agonist with the potential to be the best-in-class, and have also facilitated the development of the next generation of incretin series in our pipeline. Our R&D team has played a key role in achieving what we have today, and I want to thank each and every one of them for their hard work and selfless dedication to our accomplishments.”
Dr. Lin Xichen, Chief Scientific Officer of Structure Therapeutics, said,
“We are committed to the innovative development of new oral small molecule drugs for the treatment of a variety of chronic diseases, metabolic diseases, and pulmonary diseases. In addition, as Ray mentioned, I would also like to thank our R&D team for establishing a structure-based drug design platform and for their dedication to improving the accessibility of our drugs to patients worldwide.”
About Structure Therapeutics:
Structure Therapeutics is a leading clinical-stage biopharmaceutical company dedicated to the development of new oral therapeutic drugs for a variety of chronic, metabolic, and pulmonary diseases, addressing unmet medical needs in the market. Leveraging a next-generation structure-based drug discovery platform, the company has built a science-driven pipeline targeting GPCRs, including two wholly-owned proprietary clinical-stage small molecule compounds. These compounds overcome the limitations of traditional biologics and peptide therapies, providing treatment to an increasing number of patients.
